Harvard Dana-Farber Cancer Institute’s ASH Highlights 2025

Harvard Dana-Farber Cancer Institute’s ASH Highlights 2025

Hematology

Overview

This activity is designed to educate hematologists, oncologists, and other clinicians on new developments in the diagnosis and treatment of all blood cancers.

Through disease specific lectures, highlighting the most clinically relevant data presented at the ASH Annual Meeting, attendees will be able to identify and describe the emerging treatments available and to utilize these treatments available in their professional practice. The American Society of Hematology’s annual meeting in December is the venue at which cutting edge therapeutic advances are presented publicly for the first time.

Unfortunately, only a small fraction of practitioners can attend this meeting. It is therefore of vital importance for practitioners and, in turn, their patients to have access to emerging data in a timely fashion.

At this one-day activity, attendees will receive relevant updates on advances in acute leukemia, myelodysplasia, myeloproliferative disorders, chronic myelogenous leukemia, chronic lymphocytic leukemia, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, multiple myeloma, Waldenstrom’s macroglobulinemia, coagulation disorders, hematopoietic stem cell transplantation, and CAR-T therapies.

Course Details

• Price: $75.00
• Access Type: Lifetime
• Delivery Method: Google Drive Link, Offline
• Content Format: Mixed

What's Included

• Video lectures and recordings

Target Audience

• Physician
• Nurses
• NP
• Primary Care

Key Features

• Expert-led instruction and content
• Comprehensive coverage of topic area
• Flexible learning schedule
• Lifetime access to all materials